◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT07083960 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Ouro Medicines |
| Condition | AIHA - Warm Autoimmune Hemolytic Anemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-12 |
Trial Parameters
Condition AIHA - Warm Autoimmune Hemolytic Anemia
Sponsor Ouro Medicines
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 32
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-08-01
Completion 2026-12
All Conditions
Interventions
OM336
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Eligibility Criteria
Key Inclusion Criteria: * Active autoimmune cytopenia * Relapsed/refractory after ≥1 prior treatment * Body weight ≥ 55 kg * Willing to comply with and study requirements and procedures Key Exclusion Criteria: * Previous treatment with a BCMA-targeted therapy * Clinically significant infection within 3 months of screening * Major surgery or splenectomy within 3 months of screening or planned during the study * Pregnant or breastfeeding
Related Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology